Sample size calculation
This clinical trial was a single-arm study with ORR as the primary endpoint. In accordance with Simon’s optimal two-stage design (one-sided α 5% and power 80%), the intended sample size was 26 patients. The response rate (RR) of nivolumab in RM-NPC was 20.5%.(